Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by Creative Planning

Creative Planning increased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 13.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,564 shares of the company’s stock after buying an additional 1,283 shares during the period. Creative Planning’s holdings in Progyny were worth $302,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Progyny by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company’s stock valued at $317,097,000 after buying an additional 41,687 shares during the period. Jennison Associates LLC lifted its position in Progyny by 2.7% in the 1st quarter. Jennison Associates LLC now owns 2,596,422 shares of the company’s stock valued at $99,054,000 after purchasing an additional 67,632 shares during the last quarter. Principal Financial Group Inc. lifted its position in Progyny by 3.1% in the 1st quarter. Principal Financial Group Inc. now owns 1,400,701 shares of the company’s stock valued at $53,437,000 after purchasing an additional 42,302 shares during the last quarter. Farallon Capital Management LLC lifted its position in Progyny by 120.8% in the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after purchasing an additional 715,900 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Progyny by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company’s stock valued at $36,676,000 after purchasing an additional 254,725 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Price Performance

NASDAQ PGNY opened at $16.68 on Friday. The company’s 50 day simple moving average is $19.95 and its 200 day simple moving average is $26.03. Progyny, Inc. has a 12 month low of $13.93 and a 12 month high of $42.08. The company has a market capitalization of $1.59 billion, a P/E ratio of 27.34, a PEG ratio of 1.55 and a beta of 1.43.

Progyny (NASDAQ:PGNY) last released its earnings results on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, hitting analysts’ consensus estimates of $0.17. Progyny had a net margin of 5.54% and a return on equity of 11.97%. The business had revenue of $304.09 million for the quarter, compared to the consensus estimate of $305.32 million. During the same period in the previous year, the firm earned $0.15 EPS. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, analysts anticipate that Progyny, Inc. will post 0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on PGNY shares. Truist Financial cut their price objective on shares of Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. JPMorgan Chase & Co. cut their price objective on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, September 19th. BTIG Research downgraded shares of Progyny from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Canaccord Genuity Group cut their price objective on shares of Progyny from $24.00 to $18.00 and set a “hold” rating on the stock in a research report on Friday, September 20th. Finally, JMP Securities downgraded shares of Progyny from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 19th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $27.73.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.